AfterQuery | $30,000,000 | (Apr 10, 2026)
Plume (YC S24) | $3,900,000 | (Apr 10, 2026)
Rork | $15,000,000 | (Apr 10, 2026)
Actym Therapeutics, Inc.
United States
- Berkeley, CA
- 20/10/2023
- Series A
- $59,500,000
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.
- Industry Biotechnology Research
- Website https://actymthera.com/
- LinkedIn https://www.linkedin.com/company/actym-therapeutics-inc/about/
Related People
Christopher ThanosCo Founder
United States -
Belvedere Tiburon, California
• Significant entrepreneurial and leadership experience in the biotechnology industry
• 30 years R&D experience
• Design, engineering, and production of cell therapies, ADC's, enzymes, and alternative scaffolds
• Comprehensive understanding of pipeline flow, from lead optimization to IND, to clinical POC
• Established skills in competitive intelligence, strategy, due diligence, portfolio management
• Inventor on multiple issued patents covering biotherapeutics
• First author publications in high impact factor journals such as Science, PNAS, JACS
• Effectively managed large teams
• Invited speaker, workshop leader, conference chair at several international meetings
Haast | $12,000,000 | (Apr 10, 2026)
CareGlance Srl | $4,092,182 | (Apr 10, 2026)
Elorian AI | $55,000,000 | (Apr 10, 2026)
TeiaCare & Ancelia: AI for Care Homes | $8,184,645 | (Apr 10, 2026)
Sigma Automate | $2,750,000 | (Apr 10, 2026)
Felix(1) | $1,700,000 | (Apr 10, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
Golden Analytics | $7,000,000 | (Apr 9, 2026)